These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 33049757)

  • 21. Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L).
    Kato R; Hayashi H; Chiba Y; Miyawaki E; Shimizu J; Ozaki T; Fujimoto D; Toyozawa R; Nakamura A; Kozuki T; Tanaka K; Teraoka S; Usui K; Nishino K; Hataji O; Ota K; Ebi N; Saeki S; Akazawa Y; Okuno M; Yamamoto N; Nakagawa K
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody.
    Furuya N; Nishino M; Wakuda K; Ikeda S; Sato T; Ushio R; Tanzawa S; Sata M; Ito K
    Thorac Cancer; 2021 Mar; 12(5):613-618. PubMed ID: 33448648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
    Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
    JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
    Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B
    Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis.
    Babacan NA; Pina IB; Signorelli D; Prelaj A; Garassino MC; Tanvetyanon T
    Clin Lung Cancer; 2020 Sep; 21(5):e456-e463. PubMed ID: 32265109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of efficacy and safety between domestic immune checkpoint inhibitors and pembrolizumab in the treatment of driver gene-negative advanced non-small cell lung cancer].
    Chen YQ; Zhang YD; Yan H; Qin HY; Huang Z; Zhang X; Xiang SQ; Hu XQ; Wu F; Zhang YC; Zeng L; Yang N
    Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(4):282-289. PubMed ID: 38246773
    [No Abstract]   [Full Text] [Related]  

  • 27. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
    Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
    Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
    Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
    Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
    Park S; Choi YD; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
    Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
    Shi Y; Duan J; Guan Q; Xue P; Zheng Y
    Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study.
    Gu X; Shi Z; Shao L; Zhang Y; Zhang Y; Song Z; Wang W; Lou G
    BMC Cancer; 2022 May; 22(1):576. PubMed ID: 35606756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
    Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
    Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors.
    Ramdani HO; Falk M; Heukamp LC; Schatz S; Tiemann M; Wesseler C; Diehl L; Schuuring E; Groen HJM; Griesinger F
    Pathol Res Pract; 2021 Nov; 227():153651. PubMed ID: 34673351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer.
    Ichihara E; Harada D; Inoue K; Sato K; Hosokawa S; Kishino D; Watanabe K; Ochi N; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Lung Cancer; 2020 Jan; 139():140-145. PubMed ID: 31786476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression.
    Giroux Leprieur E; Hélias-Rodzewicz Z; Takam Kamga P; Costantini A; Julie C; Corjon A; Dumenil C; Dumoulin J; Giraud V; Labrune S; Garinet S; Chinet T; Emile JF
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
    Shibaki R; Murakami S; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Kusumoto M; Yamamoto N; Ohe Y
    Med Oncol; 2019 Apr; 36(6):49. PubMed ID: 31030326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
    Qin A; Rengan R; Lee S; Santana-Davila R; Goulart BHL; Martins R; Baik C; Kalemkerian GP; Hassan KA; Schneider BJ; Hayman JA; Jolly S; Hearn J; Lawrence TS; Towlerton AMH; Tewari M; Thomas D; Zhao L; Brown N; Frankel TL; Warren EH; Ramnath N
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):170-177. PubMed ID: 31756415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting.
    Takada K; Shimokawa M; Takamori S; Shimamatsu S; Hirai F; Tagawa T; Okamoto T; Hamatake M; Tsuchiya-Kawano Y; Otsubo K; Inoue K; Yoneshima Y; Tanaka K; Okamoto I; Nakanishi Y; Mori M
    Int J Cancer; 2021 Jul; 149(2):473-482. PubMed ID: 33720422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
    Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.